Tivdak Injection, Powder, For Solution
Product Images NDC 51144-003

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Tivdak (NDC 51144-003). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Seagen Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton (Carton)

TIVDAK (tisotumab vedotin-tftv) 40 mg/vial injection powder for solution label shows it is for intravenous use only and single-dose vial. The label includes storage instructions to refrigerate at 2°C to 8°C, manufacturer information (Seagen Inc., Bothell, WA), and cautions about reconstitution and hazardous agent status. The label also displays logos for Seagen and Genmab, and states product origin as Switzerland.*

FDA Label Image

Label (Label)

Label for TIVDAK (tisotumab vedotin) injection, powder for solution, 40 mg per vial. It is intended for intravenous infusion, single-dose vial, and requires reconstitution and dilution before use. The label includes storage instructions, manufacturer Seagen Inc., and warns it is a hazardous agent requiring protection from light and specific temperature control.*

FDA Label Image

Logo (Smalllogo)

TIVDAK 40 mg/4 mL injection, powder, for solution vial label from SEAGEN INC. The label includes the proprietary name TIVDAK, the generic name tisotumab vedotin, the dosage strength, and indicates the product is for intravenous use. Lot and expiration information fields are also visible but not specified.*

FDA Label Image

Structural Formula (Structure)

Chemical structure diagram of tisotumab vedotin showing its antibody-drug conjugate components including the IgG1 monoclonal antibody (Tisotumab), a valine-citrulline dipeptide linker, p-aminobenzyl alcohol carbamate (PABC), and the cytotoxic agent monomethyl auristatin E (MMAE). The structure highlights the drug-linker region connecting the antibody and MMAE.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.